Last reviewed · How we verify
Requip PR
Requip PR is a dopamine agonist that stimulates dopamine receptors in the brain to increase dopamine activity.
Requip PR is a dopamine agonist that stimulates dopamine receptors in the brain to increase dopamine activity. Used for Parkinson's disease, Restless legs syndrome.
At a glance
| Generic name | Requip PR |
|---|---|
| Also known as | Requip 24-hour prolonged release (PR). |
| Sponsor | Rajesh Pahwa, MD |
| Drug class | Dopamine agonist |
| Target | Dopamine D2 and D3 receptors |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Requip (ropinirole) is a non-ergot dopamine agonist that preferentially binds to dopamine D2 and D3 receptors. The prolonged-release (PR) formulation provides sustained dopamine receptor stimulation over 24 hours. This mechanism helps restore dopamine signaling in the basal ganglia, which is deficient in Parkinson's disease.
Approved indications
- Parkinson's disease
- Restless legs syndrome
Common side effects
- Nausea
- Dizziness
- Somnolence
- Hallucinations
- Orthostatic hypotension
- Headache
Key clinical trials
- Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD) (PHASE2)
- Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528 (PHASE3)
- A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa (PHASE3)
- A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease (PHASE4)
- A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease (PHASE4)
- Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects (PHASE1)
- A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's (PHASE3)
- Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |